On January 7, 2026 Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, reported it will present at the Biotech Showcase conference taking place from January 12-14, 2026, in San Francisco, California. CEO Helen Tayton-Martin will present Evaxion’s 2026 company milestones and provide a company update on January 13, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Biotech Showcase conference coincides with the J.P. Morgan Healthcare Conference and Evaxion will engage with stakeholders in San Francisco, including potential business partners, throughout the week.

Presentation details:
Date: Tuesday, January 13, 2026
Time: 2:00pm PST/11:00pm CET
Track: Yosemite C (Ballroom Level)

(Press release, Evaxion, JAN 7, 2026, View Source [SID1234661799])

On January 7, 2026 Emergent BioSolutions Inc. (NYSE: EBS) reported that Joe Papa, president and chief executive officer, will provide a company presentation during the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 5:15 PM PST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The audio link for Emergent’s session may be accessed here and will be live for up to 30 days.

The Company’s slides will be made available at the time of the presentation on the Investors section of the Emergent website.

(Press release, Emergent BioSolutions, JAN 7, 2026, View Source [SID1234661798])

On January 7, 2026 Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, reported that John Quisel, J.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14th at 3:00 pm PT / 6:00 pm ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available through the investor relations section of the Company’s website at ir.discmedicine.com and an archived replay will be available after the event.

(Press release, Disc Medicine, JAN 7, 2026, View Source [SID1234661797])

On January 7, 2026 Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, reported that it will present at Biotech Showcase taking place in San Francisco, January 12-14, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the event, members of Azitra’s management team will conduct one-on-one meetings with registered investors and potential partners, showcasing the company’s clinical development strategy, recent corporate achievements, and anticipated milestones.

Details are as follows:

Event:

Biotech Showcase 2026

Date & Time

Tuesday, January 13, 2026, 2:30 PM, PT

Location:

Hilton San Francisco Union Square, Yosemite C (Ballroom Level)

Presenter

Travis Whitfill, Chief Operating Officer

Registration:

https://informaconnect.com/biotech-showcase/registration-options/

(Press release, Azitra, JAN 7, 2026, View Source [SID1234661796])

On January 7, 2026 Artios Pharma Limited ("Artios"), a biopharmaceutical company committed to realizing the therapeutic power of targeting the DNA damage response ("DDR") in cancer, reported that it will present at the 44th Annual J.P. Morgan Healthcare Conference taking place in San Francisco from January 12 to 15, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mike Andriole, Artios’ Chief Executive Officer, will highlight the company’s strategic priorities for its two differentiated, potential first-in-class clinical programs in cancers with high unmet need. The company’s ATR inhibitor, alnodesertib, selects for ATM-deficient patients whose tumors harbor high degrees of DNA replication stress where the program has generated responses across eight different tumor types in early clinical development. It is currently being evaluated in two Phase 2 expansion cohorts in colorectal and pancreatic cancers. The company is also initiating a randomized Phase 2 study of its potentially first-in-class DNA polymerase Theta (Polθ) inhibitor, ART6043, in patients with BRCA-mutant HER2-negative breast cancer who are eligible to receive a PARP inhibitor.

The presentation will take place on Thursday, January 15, at 07:30 am PST (10:30 am EST / 03:30 pm UTC) in the Elizabethan B room (2nd floor) at The Westin St. Francis, 335 Powell Street, San Francisco.

(Press release, Artios Pharma, JAN 7, 2026, View Source [SID1234661795])